Full Press Release Details
shareholders vote in favour of all resolutions at its Annual General
DUBLIN--(BUSINESS WIRE)--July 23, 2013--ICON plc, (NASDAQ: ICLR),
a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries, today
announced that all resolutions at the Annual General Meeting of the
Company (AGM) held on 22nd July 2013 (which resolutions had
all been recommended by the Board) were all duly passed by shareholders.
These resolutions were set out in the Notice of the AGM sent to
shareholders on 14th June 2013 and are available on the
The final results of voting on each of the items submitted to a vote of
shareholders during the AGM are as follows:
| RESOLUTION NUMBER | RESOLUTION | TOTAL NUMBER OF VOTES | VOTE FOR | VOTE AGAINST | VOTE WITHHELD | ||||||||
| 1.1 | To re-elect Mr. Thomas Lynch | 51,674,203 | 51,474,431 | 133,020 | 66,752 | ||||||||
| 1.2 | To re-elect Mr. Declan McKeon | 51,674,203 | 51,506,997 | 100,445 | 66,761 | ||||||||
| 1.3 | To re-elect Prof. William Hall | 51,674,203 | 51,517,884 | 89,558 | 66,761 | ||||||||
| 2 | To receive accounts and reports | 51,674,203 | 51,409,116 | 8,517 | 256,570 | ||||||||
| 3 | To authorise the fixing of the auditors' remuneration | 51,674,203 | 47,640,947 | 3,965,491 | 67,765 | ||||||||
| 4 | To authorise the Company to allot shares | 51,674,203 | 44,580,855 | 7,013,214 | 80,134 | ||||||||
| 5** | To disapply pre-emption rights | 51,674,203 | 45,337,820 | 6,251,874 | 84,509 | ||||||||
| 6** | To authorise the Company to make market purchases of shares | 51,674,203 | 51,122,122 | 13,329 | 538,752 |
** Special Resolution. All resolutions are ordinary resolutions unless
The statements made in this press release may contain forward-looking
statements that involve a number of risks and uncertainties. In addition
to the matters described in this press release, the ability to maintain
large client contracts or enter into new contracts, maintain client
relationships and the ability to manage the opening of new offices, the
integration of new business mergers and acquisitions, as well as other
risks and uncertainties detailed from time to time in reports filed with
the US Securities and Exchange Commission by ICON, including its Form
20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON.
ICON disclaims any intent or obligation to update these forward-looking
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 78 locations in 37 countries and has
approximately 10,170 employees. Further information is available at www.iconplc.com.
Chief Financial Officer
EVP Investor Relations and Corporate Development